Age (viability testing): consensus appropriateness Therapeutic consequences: <45 years: 5.3%, criteria for CMR imaging, in centres Prospective Changes in medication 45–59 years: 17.0%, included in the EuroCMR registry multicentre Invasive procedure 60–74 years: 19.2%, Exclusion criteria: Hospital discharge >74 years: 22.4% Hospital admission NR cohort study Mean age (IQR): 60 years (range 47–70) Objective: Male: 65.5% Evaluate indications, image quality, safety and impact on patient Ethnicity: NR management of routine CMR Follow-up: Mean 400 days imaging on a European level (IQR 367–419 days) Taylor et al. () Level IV: N=92/732 patients referred Inclusion criteria: Setting: Hospital NA % of patients who had a for CMR for whom viability change in surgical Australia Quality: 9.5/12 All patients referred to the Alfred MRI machine: 1.5-T scanner using testing was done management plan Hospital in Melbourne for clinical a cardiac coil and ECG Low risk of bias CMR scanning Protocol for LGE-CMR: Inversion Prospective Age (viability testing), Exclusion criteria: recovery gradient echo sequences mean: 55.9 ± 15.0 years 10 minutes after intravenous Patients undergoing scans for administration of contrast agent cohort study Male: 83% research purposes or non-funded (0.2 mmol/kg Gd-DTPA) to indications demonstrate myocardial delayed Ethnicity: NR enhancement were performed Objective: Follow-up: 6 months Evaluate the impact of CMR imaging on cardiac device and surgical therapy CMR = cardiac magnetic resonance imaging; Gd-DTPA = gadolinium diethylenetriaminepentaacetic acid; IQR = inter-quartile range; LGE = late gadolinium enhancement; MRI = magnetic resonance imaging; NR = not reported; NA = not applicable; T = tesla Table 152 Study characteristics of therapeutic effectiveness studies (population 2) Study Study design Study population Inclusion/exclusion criteria Intervention and outcomes Country Quality appraisal
Prospective multicentre cohort study Age (viability testing): <45 years: 5.3%, 45–59 years: 17.0%, 60–74 years: 19.2%, >74 years: 22.4% Mean age (IQR): 60 years (range 47–70) Male: 65.5% Ethnicity: NR Follow-up: Mean 400 days (IQR 367–419 days) consensus appropriateness criteria for CMR imaging, in centres included in the EuroCMR registry Exclusion criteria: NR Objective: Evaluate indications, image quality, safety and impact on patient management of routine CMR imaging on a European level Therapeutic consequences: Changes in medication Invasive procedure Hospital discharge Hospital admission Taylor et al. () Australia Prospective cohort study Level IV: Quality: 9.5/12 Low risk of bias N=92/732 patients referred for CMR for whom viability testing was done Age (viability testing), mean: 55.9 ± 15.0 years Male: 83% Ethnicity: NR Follow-up: 6 months Inclusion criteria: All patients referred to the Alfred Hospital in Melbourne for clinical CMR scanning Exclusion criteria: Patients undergoing scans for research purposes or non-funded indications Objective: Evaluate the impact of CMR imaging on cardiac device and surgical therapy Setting: Hospital MRI machine: 1.5-T scanner using a cardiac coil and ECG Protocol for LGE-CMR: Inversion recovery gradient echo sequences 10 minutes after intravenous administration of contrast agent (0.2 mmol/kg Gd-DTPA) to demonstrate myocardial delayed enhancement were performed NA % of patients who had a change in surgical management plan CMR = cardiac magnetic resonance imaging; Gd-DTPA = gadolinium diethylenetriaminepentaacetic acid; IQR = inter-quartile range; LGE = late gadolinium enhancement; MRI = magnetic resonance imaging; NR = not reported; NA = not applicable; T = tesla Table 152 Study characteristics of therapeutic effectiveness studies (population 2) Study Country Study design Quality appraisal Study population Inclusion/exclusion criteria Intervention and outcomes
1237-AssessmentReport-Final.docx